Thermo Fisher Scientific was founded in 1956 and is headquartered in Waltham, US

President and Chief Executive Officer

Thermo Fisher Scientific has an office in Waltham

Waltham, US (HQ)

168 3rd Ave

Thermo Fisher Scientific's revenue was reported to be $18.3 b in FY, 2016 which is a **8% increase** from the previous period.

USD

## Revenue (FY, 2016) | 18.3 b |

## Revenue growth (FY, 2015 - FY, 2016), % | 8% |

## Gross profit (FY, 2016) | 8.4 b |

## Gross profit margin (FY, 2016), % | 46% |

## Net income (FY, 2016) | 2 b |

## EBIT (FY, 2016) | 2.4 b |

## Market capitalization (19-Jul-2017) | 70.5 b |

## Closing share price (19-Jul-2017) | 179.4 |

## Cash (31-Dec-2016) | 786.2 m |

## EV | 86.3 b |

Thermo Fisher Scientific's current market capitalization is $70.5 b.

- Source: SEC Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 13.1 b | 16.9 b | 17 b | 18.3 b |

## Revenue growth, % | 29% | 0% | 8% | |

## Cost of goods sold | 7.6 b | 9.4 b | 9.2 b | 9.9 b |

## Gross profit | 5.5 b | 7.5 b | 7.8 b | 8.4 b |

## Gross profit Margin, % | 42% | 44% | 46% | 46% |

## Operating expense total | 11.5 b | 14.4 b | 14.6 b | 15.8 b |

## EBIT | 1.6 b | 2.5 b | 2.3 b | 2.4 b |

## EBIT margin, % | 12% | 15% | 14% | 13% |

## Pre tax profit | 1.3 b | 2.1 b | 1.9 b | 2 b |

## Income tax expense | (40.4 m) | (191.7 m) | 43.9 m | 1.4 m |

## Net Income | 1.3 b | 1.9 b | 2 b | 2 b |

- Source: SEC Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 5.8 b | 1.3 b | 452.1 m | 786.2 m |

## Inventories | 1.5 b | 1.9 b | 2 b | 2.2 b |

## Current Assets | 9.9 b | 6.5 b | 5.7 b | 7 b |

## PP&E | 1.8 b | 2.4 b | 2.4 b | 2.6 b |

## Goodwill | 12.5 b | 18.8 b | 18.8 b | 21.3 b |

## Total Assets | 31.9 b | 42.9 b | 40.9 b | 45.9 b |

## Accounts Payable | 691.5 m | 820.7 m | 822.2 m | 926.2 m |

## Total Debt | 10.5 b | 14.6 b | 12.5 b | 16.6 b |

## Current Liabilities | 3.1 b | 5.3 b | 4.1 b | 4.9 b |

## Additional Paid-in Capital | 8.2 b | 11.5 b | 11.8 b | 12.1 b |

## Retained Earnings | 8.8 b | 10.4 b | 12.1 b | 13.9 b |

## Total Equity | 16.9 b | 20.5 b | 21.4 b | 21.5 b |

## EPS | 3.6 | 4.8 | 5 | 5.1 |

## Debt to Equity Ratio | 0.6 x | 0.7 x | 0.6 x | 0.8 x |

## Debt to Assets Ratio | 0.3 x | 0.3 x | 0.3 x | 0.4 x |

## Financial Leverage | 1.9 x | 2.1 x | 1.9 x | 2.1 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | 1.3 b | 1.9 b | 2 b | 2 b |

## Accounts Receivable | (147.9 m) | (145.4 m) | (149.4 m) | (352.2 m) |

## Inventories | (72.2 m) | (109.8 m) | (140.7 m) | 97.8 m |

## Accounts Payable | 47 m | 1.2 m | (2.7 m) | 55.5 m |

## Cash From Operating Activities | 2 b | 2.6 b | 2.8 b | 3.2 b |

## Capital Expenditures | (282.4 m) | (427.6 m) | (422.9 m) | (444.4 m) |

## Cash From Investing Activities | (263.3 m) | (11.8 b) | (1.1 b) | (5.5 b) |

## Dividends Paid | (216.2 m) | (234.8 m) | (240.6 m) | (238.4 m) |

## Cash From Financing Activities | 3.3 b | 4.8 b | (2.5 b) | 2.9 b |

## Free Cash Flow | 2.3 b | 3 b | 3.2 b | 3.6 b |

USD | Y, 2016 |
---|---|

## P/E Ratio | 35 |

## EV/EBIT | 35.2 x |

## EV/CFO | 27.3 x |

## EV/FCF | 24 x |

## Revenue/Employee | 351.4 k |

## Debt/Equity | 0.8 x |

## Debt/Assets | 0.4 x |

## Financial Leverage | 2.1 x |

Thermo Fisher Scientific's Customers was reported to be 400 k in FY, 2016

- Source: SEC Filings

Acquired Company | Date | Deal Size |
---|---|---|

Core Informatics | March 07, 2017 |

Source: 125 public H-1B filings from Thermo Fisher Scientific